Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SafiledCriticalItalfarmaco Sa
Publication of ECSP11010870ApublicationCriticalpatent/ECSP11010870A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere al uso de estriol en la preparación de una formulación farmacéutica de administración vaginal con la capacidad de autolimitar la absorción de estriol, para la prevención y/o el tratamiento de atrofia urogenital en mujeres, teniendo dichas mujeres una alta probabilidad de desarrollar un tumor estrógeno-dependiendo o que padecen o han padecido un tumor estrógeno-dependiente.The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the ability to self-limit the absorption of estriol, for the prevention and / or treatment of urogenital atrophy in women, said women having a high probability of develop an estrogen-dependent tumor or suffer from or have suffered an estrogen-dependent tumor.
ECSP110108702008-08-072011-03-04
TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH RISK OF TUMOR PATHOLOGY
ECSP11010870A
(en)
Pharmaceutical formulation comprising mixture of anti-alpha4beta7 antibody, a buffering agent, and citrate; use of said formulation to treat inflammatory bowel disease.
USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
Pharmaceutical composition comprising (-) - carvone, (+) - carvone, trans-geraniol and at least one component chosen from essential oils for use in the treatment and prevention of viral diseases.
Pharmaceutical combination comprising at least one 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol of formula (i) and at least one nmda antagonist; pharmaceutical composition; and use for pain treatment.
Compounds derived from resolviin; pharmaceutical composition; use of the composition; pharmaceutical kit; pharmaceutical combination; use of the compounds in the treatment and / or prevention of an ophthalmic condition.
Compositions comprising extracts of andrographis paniculata combined with extracts of ginkgo biloba complexed with phospholipids; and its use in the preparation of a medicament for the treatment of Alzheimer's and multiple sclerosis.